logo
Near Ukraine front, Svitanok organisation a haven for outcasts

Near Ukraine front, Svitanok organisation a haven for outcasts

WHENEVER warm days come to Kramatorsk, near the eastern Ukrainian front, the Svitanok organisation leaves its door wide open, offering advice or a cup of tea to the city's social outcasts.
People living with HIV, those recovering from drug addiction, sex workers – all are welcome to seek medical guidance and respite from stigma and solace as Russian troops advance toward Kramatorsk.
The refuge they find at Svitanok is vital during the war, when marginalised communities often feel left behind and face heightened insecurity and stigma.
"They support me here, they respect me. I just came to drink some tea. They'll treat me, I know they'll accept me," says Oleg Makaria, who is HIV-positive.
Makaria, who comes to Svitanok most days, hardly reacts to the air raid sirens once again wailing in Kramatorsk, just 20 kilometres (12 miles) from the front.
The 41-year-old jokes that he does not look his age. But he suddenly breaks down thinking about Donetsk, his home city now in Russian hands.
"I understand I can't return to Donetsk anymore. Never in my life. Probably... I'm here alone," he mutters through tears.
Moscow-backed separatists seized parts of the Donetsk region in 2014, a prelude to the Kremlin's full-scale 2022 invasion, which the UNHCR says has displaced nearly 11 million people.
The conflict disrupted treatment – which needs to be taken daily to control HIV – to some of the 250,000 Ukrainians estimated by UNAIDS to be living with the infection in 2020.
Advances from Russian troops have also threatened drug treatment programmes.
Moscow and its proxies have banned opioid substitution, which replaces dangerous opioids with less harmful substances such as methadone.
Approved by the United Nations and the World Health Organisation, the treatment also reduces HIV transmission as it lowers drug injections.
No one would guess looking at Natalia Zelenina, but the bright social worker sporting a red bob and bright pink lipstick spent five years in Russian custody.
She was carrying legally prescribed drugs for her replacement therapy when she was stopped by Moscow-backed separatists controlling parts of the Donetsk region in 2017.
"I realised how strong I was," the 52-year-old said.
While her colleagues campaigned to get her out, she fought to obtain treatment for her HIV.
"I survived, I endured it all. I went through it all. I didn't break," she said.
After being released to Kyiv-controlled territory in a prisoner exchange, Zelenina returned to Svitanok.
"I knew that I could only recover in a familiar atmosphere," she says.
But even in the protective bubble of Svitanok, where most workers have HIV and a drug dependency, the boom of explosions can be heard in the distance.
One employee told AFP she started consuming "just a little bit" of drugs to alleviate her anxiety – until her colleagues helped her get clean again.
Iryna Mamalakieva arrives holding her four-year-old son Maksym, who wobbled off at any opportunity to pick dandelions on a patch of grass.
The unemployed 31-year-old former mine operator, diagnosed with HIV in 2019, relies on Svitanok for medical and legal help.
"Some people give up, some hang themselves. I knew people like that: They found out about their diagnosis, and even if they had children, they drank themselves to death and quietly went to hang themselves," she said.
The war has exacerbated stigma towards HIV-positive people and those suffering from drug addictions, counsellor Svitlana Andreieva told AFP.
"The rest of the world that's outside our doors, it tells them that they are nobody, that they're not accepted, they're not respected," she said.
Andreieva herself remembers being kicked out of hospitals and beaten up by the police because she was addicted to drugs and HIV-positive.
Then she learned law, which she shares with visitors who went through similar experiences.
"The next time they don't come with tears," she said. "They say: 'What do I need to do, which law article should I rely on?'"
But Andreieva's patience is often tested.
After an altercation with a regular, she finds a bouquet of lilacs in lieu of apologies in the office. Hard to win over, she initially shrugs it off.
But Svitanok's workers and beneficiaries face yet another hurdle: cuts in US humanitarian aid.
Svitanok has for now survived Washington's aid freeze, but is scrambling to find alternative sources of funding for some of its many programmes, which partly rely on US money.
The uncertainty "really knocked me out of my stability", Zelenina says.
"There's such a melancholy in my soul, you know? I love my job. I simply can't imagine what I will do tomorrow."

Orange background

Try Our AI Features

Explore what Daily8 AI can do for you:

Comments

No comments yet...

Related Articles

Rise in antibiotic-resistant sexually transmitted infections
Rise in antibiotic-resistant sexually transmitted infections

The Star

time2 days ago

  • The Star

Rise in antibiotic-resistant sexually transmitted infections

If you're having unprotected sex with a new or casual partner, get yourself tested for STIs annually even if there are no symptoms. — Freepik There has been a 'concerning jump' in cases of gonorrhoea resistant to strong antibiotics, health officials have warned. New figures from the United Kingdom Health Security Agency (UKHSA) show there have been more cases of the sexually transmitted infection (STI) gonorrhoea that are resistant to the antibiotic ceftriaxone so far in 2025 than the whole of last year. Overall, there was a 16% drop in gonorrhoea cases in 2024 in England, with 71,802 diagnoses, compared with 85,370 in 2023. However, ceftriaxone-resistant gonorrhoea cases are being detected more frequently – with 14 in the first five months of 2025 compared with 13 in 2024. Six of the 14 cases this year have been 'extensively drug-resistant,' which means that they were resistant to ceftriaxone and then to second-line treatment options, according to the UKHSA. Ceftriaxone is a strong antibiotic and the main treatment for gonorrhoea. Experts are therefore concerned when infections fail to respond to it. Most of these drug-resistant cases are linked with travel to or from the Asia-Pacific region, where the prevalence of ceftriaxone resistance is high. Elsewhere, among people in England, early-stage syphilis diagnoses rose 1.7%, from 9,375 in 2023 to 9,535 in 2024. The overall figure for syphilis, including late-stage syphilis or complications from the infection, increased 5% from 12,456 in 2023 to 13,030 in 2024. Chlamydia fell 13%, from 194,143 diagnoses in 2023 to 168,889 in 2024, while people diagnosed for the first time with genital warts also dropped. Among women aged 15 to 24 who are recommended to be screened through the National Chlamydia Screening Programme (NCSP), there was a 10.7% decrease in the number of chlamydia tests carried out, from 673,102 to 601,295. Dr Hamish Mohammed, consultant epidemiologist at UKHSA, said: 'Levels of STIs in this country remain a big threat to sexual well-being. 'These infections can have a major impact on your health and that of any sexual partners – particularly if they are antibiotic resistant. 'If you've had condomless sex with new or casual partners – either in the UK or overseas – get tested for STIs and HIV at least yearly, even if you don't have symptoms. 'Regular testing protects both you and those you're having sex with. 'From August, eligible people will also be offered vaccination to reduce the risk of gonorrhoea and we expect to see the immunisation programme have an impact on diagnoses of this infection in coming years.' Professor Matt Phillips, president of the British Association for Sexual Health and HIV, said: 'Whilst it is encouraging to see a fall in the total number of STI diagnoses this year, we nonetheless continue to see historically high rates of sexual infection, with particularly worrying continued increases in infections such as syphilis, which are at their highest-ever levels, and the continued spread of antibiotic-resistant disease.' It is vital that clear steps are put in place to reverse these trends. He added: 'Sexual health services remain under immense pressure and these new tools risk being deployed into overstretched systems unable to support them effectively. 'We find ourselves at a critical point for securing the long-term viability of sexual health services in this country. 'Only a joined-up, ambitious national strategy can ensure that we are prepared not just for today's sexual health challenges, but for those we know are coming.' – PA Media/dpa

New hope for patients with less common breast cancer
New hope for patients with less common breast cancer

Sinar Daily

time2 days ago

  • Sinar Daily

New hope for patients with less common breast cancer

WASHINGTON - A new treatment nearly halves the risk of disease progression or death from a less common form of breast cancer that hasn't seen major drug advances in over a decade, researchers reported recently. Results from the study, presented at the annual meeting of the American Society for Clinical Oncology, are expected to be submitted to regulators and could soon establish a new first-line therapy for people with HER2-positive metastatic breast cancer -- the advanced stage of a form that comprises 15-20 per cent of all breast cancer cases. Patients with HER2-positive breast cancer that has spread to other parts of the body live around five years. - 123RF file photo HER2-positive cancers are fueled by an overactive HER2 gene, which makes too much of a protein called human epidermal growth factor receptor 2 that helps cancer cells grow and spread. Patients with HER2-positive breast cancer that has spread to other parts of the body live around five years. "Seeing such a striking improvement was really impressive to us -- we were taking a standard and almost doubling how long patients could have their cancer controlled for," oncologist Sara Tolaney, chief of the breast oncology division at Dana-Farber Cancer Institute, told AFP. The current standard of care, known as THP, combines chemotherapy with two antibodies that block growth signals from the HER2 protein. The new approach uses a drug called trastuzumab deruxtecan (T-DXd), an antibody attached to a chemotherapy drug. 'Smart bomb' This "smart bomb" strategy allows the drug to target cancer cells directly. "You can bind to the cancer cell and dump all that chemo right into the cancer cells," explained Tolaney. "Some people call them smart bombs because they're delivering chemo in a targeted fashion -- which is how I think we're able to really increase efficacy so much." Common side effects included nausea, diarrhea and a low white blood cell count, with a less common effect involving lung scarring. T-DXd is already approved as a "second-line" option -- used when first-line treatments stop working. But in the new trial, it was given earlier, paired with another antibody, pertuzumab. In a global trial led by Tolaney, just under 400 patients were randomly assigned to receive T-DXd in combination with pertuzumab, thought to enhance its effects. A similar number received the standard THP regimen. A third group, who received T-DXd without pertuzumab, was also enrolled -- but those results haven't yet been reported. 44 per cent risk reduction At a follow-up of 2.5 years, the T-DXd and pertuzumab combination reduced the risk of disease progression or death by 44 per cent compared to standard care. Fifteen per cent of patients in the T-DXd group saw their cancer disappear entirely, compared to 8.5 per cent in the THP group. Because this was an interim analysis, the median progression-free survival -- meaning the point at which half the patients had seen their cancer return or worsen -- was 40.7 months with the new treatment, compared to 26.9 months with the standard, and could rise further as more data come in. Tolaney said the results would be submitted to regulators around the world, including the US Food and Drug Administration, and that future work would focus on optimising how long patients remain on the treatment, particularly those showing complete remission. "This represents a new first-line standard treatment option for HER2-positive metastatic breast cancer," said Dr. Rebecca Dent, a breast cancer specialist at the National Cancer Center Singapore who was not involved in the study. - AFP

Gaza doctors donate blood to save patients amid aid distribution carnage
Gaza doctors donate blood to save patients amid aid distribution carnage

New Straits Times

time2 days ago

  • New Straits Times

Gaza doctors donate blood to save patients amid aid distribution carnage

GENEVA: Doctors in the Gaza Strip are donating their own blood to save their patients after scores of Palestinians were gunned down while trying to get food aid, the medical charity Doctors Without Borders (MSF) said on Thursday. Around 100 MSF staff protested outside the UN headquarters in Geneva against an aid distribution system in Gaza run by an Israeli-backed private company, which has led to chaotic scenes of mass carnage. "People need the basics of also need it in dignity," MSF Switzerland's director general, Stephen Cornish, told Reuters at the protest. "If you're fearing for your life, running with packages being mowed down, this is just something that is completely beyond everything we've ever seen," he said. "These attacks have killed were left to bleed out on the ground." Cornish said staff at one of the hospitals where MSF operates had to give blood, as most Palestinians are now too poorly nourished to donate. Israel allowed the private Gaza Humanitarian Foundation to begin food distribution in Gaza last week, after having completely shut the Gaza Strip to all supplies since the beginning of March. Gaza authorities say at least 102 Palestinians were killed and nearly 500 wounded trying to get aid from the food distribution sites in the first eight days. Eyewitnesses have said Israeli forces fired on crowds. The Israeli military said Hamas fighters were to blame for opening fire, though it acknowledged that on Tuesday, when at least 27 people died, its troops had fired at "suspects" who approached their positions. The United States vetoed a UN Security Council resolution on Wednesday, supported by all other Council members, which would have called for an "immediate, unconditional and permanent ceasefire" in Gaza and unhindered access for aid. — REUTERS

DOWNLOAD THE APP

Get Started Now: Download the App

Ready to dive into the world of global news and events? Download our app today from your preferred app store and start exploring.
app-storeplay-store